(71) Epidemiology Assessment of Poly-Pharmacy Among Metabolic Syndrome Patients Based on Prescriptions of Iranians Health Insurance Service Data Sets, a Cross Sectional Study

Friday, August 26, 2022

8:00 AM – 6:00 PM CEST

Location: Hall C

Publication Number: 402

Presenting Author(s)

Mojdeh Daneshmand, PharmD
– Doctor, Shahid Beheshti University of Medical Science, Shaheed Beheshti Medical University, Tehran, Tehran, Iran

Co-Author(s)

Hamidreza Jamshidi
– Professor, Professor, department of pharmacology, school of medicine, Shahid Beheshti University of Medical Science, Iran
Farshad Farzadfar
– Professor, Non-communicable Disease Research Center (NCDRC), Tehran, Iran, Iran
MohammadHadi Farjoo
– Professor, Assistant Professor, department of pharmacology, school of medicine, Shahid Beheshti University of Medical Science, Tehran, Iran
Salehe Mortazavi
– Professor, Assistant Professor of Gerontology (MBA,MPH, PhD), Iran University of Medical Sciences, Iran
Mohsen Shati
– Professor, Assistant Professor of Epidemiology, Social Injury Prevention Research Institute, Iran University of Medical Sciences, Iran

Background: Metabolic Syndrome is one of the most prevalent diseases around the world. Since there are various complications related to this disease, it is a real challenge for clinicians to prescribe the most functional series of medications for these patients. In the treatment process of such diseases, multi-drug prescriptions, known as “Poly-pharmacy” are common. Many factors are associated with this issue and it has several untoward consequences and impacts on patients’ health and their treatment process.

Objectives: The aim of this study was to evaluate the epidemiology of poly-pharmacy among the metabolic syndrome patients in Iran at national level between 2015 and 2016, and to assess its correlation with socioeconomic and demographic factors. Then we evaluated the epidemiology of Potentially Inappropriate Medication (PIM) among patients over 60 years with and without poly-pharmacy and assessed its correlation with poly-pharmacy and other socio-economic and demographic factors

Methods: A population based cross sectional study was performed following overlapping data from Iranians Health Insurance Service prescriptions between 2015 and 2016 with patients data from STEPS Iran 2016 study. Epidemiology of poly-pharmacy was evaluated among 2075 metabolic syndrome patients and then, correlation between poly-pharmacy and socioeconomic and demographic factors was assessed using multi-variate regression analysis . Patients 60 years and above with metabolic syndrome were considered as elderly, and then epidemiology of PIM (Potentially Inappropriate Medication) was evaluated through their prescriptions based on American Geriatrics Society Beers Criteria 2019 (AGSBC).The correlation of PIM with poly-pharmacy and other socioeconomic and demographic factors was evaluated as well using multi-variate regression analysis.

Results: Out of 2075 metabolic syndrome patients between 2015 and 2016, 10.3% (214) had prescriptions with poly-pharmacy. Among socioeconomic and demographic factors, significant correlation of poly-pharmacy with age, area of living and job was observed (P value < 0.001). In 2015 and 2016 combined, prevalence of PIM was 6.6% and 46.1% in prescriptions without and with poly-pharmacy respectively. Significant correlation was observed between area of living, poly-pharmacy and PIM (P value < 0.001).

Conclusions: Poly-pharmacy has a significant relationship with certain sociodemographic factors, therefore preventive measures should be taken to avoid adverse effects of poly-pharmacy among metabolic syndrome patients.